Business
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has regained exclusive distribution rights for TULSA-PRO® in Canada from Knight Therapeutics Inc. (“Knight”). The TULSA Procedure™, performed using the TULSA-PRO system
About this update from Knight Therapeutics, Inc.
[{"type":"image","alt":"Profound Medical Corp.","displaySize":"","headline":null,"caption":"Profound Medical Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/706e95b61981393723638191940b98c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oleh9hsLn64FmkZjOMsmoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/706e95b61981393723638191940b98c5","width":300,"height":39}},"lazy":false},{"type":"text","content":"TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has regained exclusive distribution rights for TULSA-PRO® in Canada from Knight Therapeutics Inc. (“Knight”).","length":441,"tagName":"p"},{"type":"text","content":"The TULSA Procedure™, performed using the TULSA-PRO system, is used by physicians to ablate prostate tissue in men suffering from prostate cancer and/or benign prostatic hyperplasia (“BPH”, also known as an enlarged prostate).","length":226,"tagName":"p"},{"type":"text","content":"Pursuant to an agreement entered into with Knight in April 2015, Knight had acted as Profound’s exclusive distributor for the technology in Canada. Profound has now regained the Canadian TULSA-PRO distribution rights from Knight in return for a one-time cash payment of CDN$90,000 (US$64,000) and a 5% royalty on Canadian Net Sales for 15 years.","length":345,"tagName":"p"},{"type":"text","content":"“Knight has been a strong supporter of Profound and its groundbreaking TULSA technology for the treatment of prostate disease, including cancer and/or BPH,” said Samira Sakhia, President and CEO of Knight. “Knight's strategy across Canada and Latin America is to commercialize innovative pharmaceutical products. The launch of TULSA-PRO in Canada, a complex medical device technology, will be served best by Profound’s North American integrated commercial and clinical teams."","length":485,"tagName":"p"},{"type":"text","content":"“Currently, there is just one (but important) Canadian site offering the TULSA Procedure,” commented Profound’s CEO...